FIERCE Pharma 2026 panel ties GLP-1 avoidance to stigma, misinformation
Conference coverage says cultural stigma and false claims may keep eligible patients from starting GLP-1 receptor agonists.
MH
By Maren Holt · Senior Reporter, GLP-1
Sep 16 00:00 ETSource: Endocrinology Advisor
The wire
- 01Speakers at FIERCE Pharma 2026 said cultural stigma and misinformation contribute to avoidance of GLP-1 receptor agonists.
- 02Uptake barriers affect treatment access for obesity and diabetes populations.
- 03Specific data, populations studied and proposed interventions are not detailed in the coverage.
From the source
Read at news.google.comFIERCE Pharma 2026: Cultural Stigma, Misinformation May Contribute to Avoidance of GLP-1 RAs